NYSE$ELAN
Elanco Animal Health Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Elanco's Q3 2024 financial results were reported, with revenue of $1,030 million and organic constant currency growth of 1%.
Elanco Animal Health reported its Q3 2024 financial results, achieving revenue of $1,030 million with 1% organic constant currency growth. The company received U.S. FDA approval for Zenrelia™ and Credelio Quattro™, and tightened its full-year 2024 financial guidance.
- Revenue reached $1,030 million, with organic constant currency growth of 1%.
- Reported EPS was $0.73, and Adjusted EPS was $0.13.
- U.S. FDA approved Zenrelia™ and Credelio Quattro™.
- Full-year 2024 revenue guidance tightened to $4,420 to $4,450 million, with 3% organic constant currency growth.
Headline financials
Revenue & EPS history
Elanco · Revenue · Quarterly
$1.03B
Revenue by segment
Elanco · $1.58B total across 5 segments · Q3 2023
- Farm Animal$561M—35.6%
- Pet Health$495M+5.1%31.4%
- Cattle$242M+3.9%15.4%
- Poultry$184M+15.7%11.7%
- Swine$93M+10.7%5.9%
Forward guidance
Elanco is tightening financial guidance for the full year 2024 and providing guidance for the fourth quarter of 2024.
Tailwinds
- Revenue between $1.00 billion and $1.03 billion is anticipated for Q4 2024.
- Organic constant currency revenue growth of 1% to 4% is expected in Q4 2024.
- Full year 2024 revenue is projected to be between $4,420 to $4,450 million.
- Full year 2024 organic constant currency growth is expected to be 3%.
- Innovation sales contribution is expected between $420 million to $450 million for the full year.
Headwinds
- Reported net loss is expected to be between $(59) million and $(32) million for Q4 2024.
- The impact of foreign exchange rates on revenue is expected to be a headwind of approximately $5 million in Q4 2024.
- The impact of foreign exchange rates on revenue is now expected to be a headwind of approximately $25 million for full year 2024.
- Gross margin headwinds from product mix and manufacturing performance are expected.
- Underlying adjusted EBITDA growth in 2025 is impacted by an anticipated $25 million to $35 million year-over-year headwind from the court-supervised insolvency of a key U.K-based contract manufacturing partner.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+2.0%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+1.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+27.2%
Q1 2024
Best reaction
-16.3%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.9% | -5.6% | +2.6% | |
| Q4 2025 | +7.3% | +6.7% | -0.7% | |
| Q3 2025 | -4.2% | -1.0% | -2.7% | |
| Q1 2025 | +26.2% | +34.8% | +46.2% | |
| Q4 2024 | -3.7% | +0.5% | -2.7% | |
| Q3 2024 | +9.4% | +9.8% | -2.8% | |
| Q2 2024 | +5.3% | +12.6% | +21.9% | |
| Q1 2024 | +27.2% | +25.7% | +34.7% | |
| Q4 2023 | +0.5% | -2.1% | -1.2% | |
| Q3 2023 | +15.9% | +14.1% | +36.4% | |
| Q2 2023 | +7.0% | +4.5% | +2.7% | |
| Q1 2023 | -3.8% | -8.4% | -0.1% | |
| Q4 2022 | -6.9% | -11.0% | -33.1% | |
| Q3 2022 | -10.3% | +0.4% | -6.7% | |
| Q2 2022 | -1.6% | +3.3% | -23.9% | |
| Q1 2022 | -7.9% | -6.4% | +1.5% | |
| Q4 2021 | +8.2% | +12.4% | +3.3% | |
| Q3 2021 | +1.2% | +0.3% | -14.3% | |
| Q2 2021 | -16.3% | -12.3% | -4.2% | |
| Q1 2021 | +3.8% | +3.4% | +10.1% | |
| Q4 2020 | +2.8% | +9.0% | -9.8% | |
| Q3 2020 | -4.7% | -8.0% | -9.8% | |
| Q2 2020 | +11.7% | +17.3% | +37.7% | |
| Q1 2020 | -13.5% | -12.9% | +3.6% | |
| Q4 2019 | -0.7% | -1.4% | -42.5% | |
| Q3 2019 | -1.9% | -3.1% | -1.2% | |
| Q2 2018 | -4.8% | -1.3% | -4.6% | |
| Q2 2019 | -4.8% | -1.3% | -4.6% | |
| Q1 2019 | +6.1% | +3.9% | +4.1% | |
| Q4 2018 | -2.4% | -1.7% | -2.7% | |
| Q3 2018 | +3.7% | +3.7% | -1.9% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro